MMAC1 gene therapy (Schering-Plough)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameMMAC1 gene therapy (Schering-Plough)
Drug Alias NameMMAC/PTEN gene therapy (Schering-Plough/Myriad)Ad-MMAC (Schering-Plough/Myriad)
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector
Mechanisms of ActionPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN modulators
TargetsPhosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Therapy Area/IndicationsGliomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMyriad Genetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSchering-Plough Corp
Active IndicationsN/A
Inactive IndicationsGliomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A